MedTrace Logo

A Clinical Study to Evaluate the Efficacy and Safety of CKD-351

NCT03762369 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 384

Last updated 2018-12-03

No results posted yet for this study

Summary

The purpose of this study is to evaluate efficacy and safety of CKD-351.

Conditions

Interventions

DRUG

CKD-351

twice a day

DRUG

Latanoprost

once a day

DRUG

D930

three times a day

DRUG

Placebo of CKD-351

once a day

DRUG

Placebo of CKD-351

twice a day

DRUG

Placebo of D930

three times a day

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • KiHo Park · Seoul National University Hosipital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-07
Primary Completion
2022-02-28
Completion
2022-05-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03762369 on ClinicalTrials.gov